Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 8/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GNG2 | P59768 | 1/20 | 0.36 |
| ▸ | GNB1 | P62873 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3839942 | 0.81 | MAPK14 (0.57) | MAPK14PDK2PDK4PGRSMN1; SMN2 | |
| SCHEMBL20594659 | 0.81 | MAPK14 (0.72) | MAPK14PDK2PDK4PGRKDM4E | |
| SCHEMBL29906734 | 0.81 | MAPK14 (0.57) | MAPK14PDK2PDK4PGRSMN1; SMN2 | |
| SCHEMBL4793061 | 0.80 | MAPK14 (0.56) | MAPK14PDK2PDK4PGRKDM4E | |
| SCHEMBL16323842 | 0.79 | ALDH1A1 (0.60) | MAPK14PDK2PDK4PGRKDM4E | |
| SCHEMBL12467499 | 0.78 | RARB (0.56) | GSK3BPTPN1ALDH1A1GNG2GNB1 | |
| SCHEMBL29825095 | 0.77 | MAPK14 (0.53) | MAPK14PDK2PDK4PGRKDM4E | |
| SCHEMBL16321516 | 0.77 | MAPK14 (0.53) | MAPK14PDK2PDK4PGRKDM4E | |
| SCHEMBL9207003 | 0.75 | MAPK14 (0.58) | MAPK14PDK2PDK4PGRKDM4E | |
| SCHEMBL7428391 | 0.74 | PDE4A (0.43) | GSK3BPTPN1PGRALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385050-B2 | Indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-08-20 | — | — | US | disclosed |
| EP-3145923-B1 | INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-C]PYRIDIN-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-01-30 | — | — | EP | disclosed |
| US-20190016719-A1 | INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-10112938-B2 | Indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-3145923-A1 | INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-03-29 | — | — | EP | disclosed |
| US-20170057960-A1 | INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057960-A1 | INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-03-02 | — | — | US | disclosed |
| WO-2015177110-A1 | INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-26 | — | — | WO | disclosed |
| US-4818755-A | Bicyclic heteroaryl thiazole compounds, cardiotonic compositions including the same, and their uses | RORER PHARMACEUTICAL CORPORATON (US) | 1989-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385050-B2 | Indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives | TPH1, TPH2, HTR1A | MAPK14 4111/4885PDK2 397/4885PDK4 921/4885 |
| US-20190016719-A1 | INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES | TPH1, TPH2, HTR1A | MAPK14 4111/4885PDK2 397/4885PDK4 921/4885 |
| US-20170057960-A1 | INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES | TPH1, TPH2, HTR1A | MAPK14 4111/4885PDK2 397/4885PDK4 921/4885 |
| US-10112938-B2 | Indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives | TPH1, TPH2, HTR1A | MAPK14 4111/4885PDK2 397/4885PDK4 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.